{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:54Z","timestamp":1789644894407,"version":"4.0.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)\u2013directed chimeric antigen receptor T-cell (CAR-T) therapy, has transformed the management of relapsed or refractory multiple myeloma and demonstrated long-term, treatment-free remissions in patients (CARTITUDE-1: median overall survival, 60.7 months and 33% of patients with progression-free survival \u22655 years). While pivotal clinical trials have demonstrated unprecedented depth and durability of response, the real-world populations can sometimes diverge from trial-eligible cohorts, with greater age variability, comorbidity burden, functional limitations, and logistic challenges that may impact outcomes. As cilta-cel adoption expands across treatment centers into the community and outpatient settings, generating real-world evidence and best practices is critical to ensuring that the transformative potential of this therapy is realized safely and effectively. This is a single-center report on our experience implementing cilta-cel. We share practical strategies that have supported favorable safety and clinical outcomes across the treatment continuum\u2014beginning with patient selection, baseline risk assessment and pre-infusion optimization, through acute monitoring and management of adverse events, to longer-term follow-up. We highlight the importance of structured workflows, multidisciplinary coordination, early referral pathways, anticipatory guidance, and collaborative care models in achieving safe and effective outcomes. As centers continue to refine cilta-cel implementation, these institutional insights will play a key role in shaping best practices for patients receiving CAR-T therapy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1841031","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:57:36Z","timestamp":1783328256000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center"],"prefix":"10.3389","volume":"16","author":[{"given":"Leyla O.","family":"Shune","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center","place":["Kansas, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center","place":["Kansas, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center","place":["Kansas, KS, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02404-6","article-title":"LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma - 2-year follow-up (final analysis)","volume":"38","author":"Mateos","year":"2024","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-186616","article-title":"Real-world clinical outcomes among triple-class exposed multiple myeloma patients and subgroups in the US oncology network","volume":"142","author":"Rifkin","year":"2023","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70145","article-title":"Real-world treatment patterns and clinical outcomes among patients with triple-class-exposed and BCMA-exposed multiple myeloma within the United States","volume":"6","author":"Mian","year":"2025","journal-title":"EJHaem"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3390\/cancers16172931","article-title":"Updates on therapeutic strategies in the treatment of relapsed\/refractory multiple myeloma","volume":"16","author":"Parekh","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.01.014","article-title":"Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable","volume":"24","author":"Ailawadhi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00760","article-title":"Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000967720.61024.68","article-title":"S202: CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Munshi","year":"2023","journal-title":"Hemasphere"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B10","unstructured":""},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00320-x","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina","year":"2025","journal-title":"Lancet Haematol"},{"key":"B12","first-page":"6","article-title":"Earlier use of ciltacabtagene autoleucel (Cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study","author":"Parekh","year":"2025"},{"key":"B13","article-title":"Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update","author":"Mateos","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408892","article-title":"Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4","volume":"15","author":"Hansen","year":"2024","journal-title":"Front Immunol"},{"key":"B15","article-title":"Comparative cost-per-responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide refractory multiple myeloma","author":"Hansen","year":"2024"},{"key":"B16","unstructured":""},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100913","article-title":"Reality check: real-world evidence to support therapeutic development in hematologic Malignancies","volume":"53","author":"Derman","year":"2022","journal-title":"Blood Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.01.002","article-title":"From vision to viability: developing infrastructure for cell and gene therapy programs","volume":"32","author":"Mahmoudjafari","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.10.025","article-title":"Who is eligible for chimeric antigen receptor T cell therapy? Expert perspectives on overcoming referral barriers","volume":"32","author":"Shadman","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166454","article-title":"Advancing CAR T-cell care in relapsed\/refractory multiple myeloma: insights from a collaborative quality improvement initiative","volume":"140","author":"Ailawadhi","year":"2022","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jadpro.2025.16.7.25","article-title":"Understanding the role and clinical management of bridging therapy during CAR T-cell therapy for relapsed or refractory multiple myeloma","author":"Hwa","year":"2025","journal-title":"J Adv Pract Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clml.2025.08.005","article-title":"Optimizing selection of bridging therapies prior to CAR-T therapy administration for multiple myeloma: clinical pearls from an expert roundtable","volume":"26","author":"Ailawadhi","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"B29","first-page":"6","article-title":"Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma","author":"Dhakal","year":"2025"},{"key":"B30","first-page":"6","article-title":"Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma","author":"Hansen","year":"2025"},{"key":"B31","first-page":"6","article-title":"Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality","author":"Sidana","year":"2025"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029773","article-title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy","volume":"146","author":"Dhakal","year":"2025","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"key":"B36","volume-title":"CARVYKTI\u00ae (ciltacabtagene autoleucel) [Prescribing Information]","year":""},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405452","article-title":"Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma","volume":"15","author":"Hansen","year":"2024","journal-title":"Front Immunol"},{"key":"B38","unstructured":"Mayo Stratification for Myeloma and Risk-Adapted Therapy"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2476382","article-title":"Establishing a successful outpatient CAR T-cell program with cilta-cel: real-world experience from an expert roundtable","volume":"21","author":"Alsina","year":"2025","journal-title":"Future Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.46989\/001c.115793","article-title":"Outpatient CAR T-cell therapy as standard of care: current perspectives and considerations","volume":"6","author":"Gatwood","year":"2024","journal-title":"Clin Hematol Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.008","article-title":"Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.21203\/rs.3.rs-4727434\/v1","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04121-8","article-title":"CD4(+) T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy","volume":"32","author":"Ho","year":"2026","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41408-025-01410-w","article-title":"Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and -4","volume":"15","author":"Rodriguez-Otero","year":"2025","journal-title":"Blood Cancer J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1396490","article-title":"Mechanisms and management of CAR T toxicity","volume":"14","author":"Ferreri","year":"2024","journal-title":"Front Oncol"},{"key":"B47","article-title":"Absolute lymphocyte count as a key biomarker for monitoring safety after ciltacabtagene autoleucel infusion","author":"Lin","year":"2025"},{"key":"B48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41408-025-01441-3","article-title":"Clinical course, risk factors and mitigating strategies for immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma","volume":"16","author":"Lim","year":"2025","journal-title":"Blood Cancer J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287783","article-title":"Cytopenias and infections following ciltacabtagene autoleucel in heavily pretreated relapsed or refractory multiple myeloma","volume":"111","author":"Dima","year":"2026","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(24)01908-6","article-title":"Effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy in the phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma","author":"Anguille","year":"2024"},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-209232","article-title":"Long-term benefits in patient-reported outcomes and time to next anti-myeloma therapy of ciltacabtagene autoleucel versus standard of care for patients with lenalidomide-refractory multiple myeloma: results from the phase 3 CARTITUDE-4 clinical trial","author":"Bar","year":"2024"},{"key":"B52","unstructured":"Fda News Release Details"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.281","article-title":"Remote patient monitoring (RPM) technology with centralized virtual nurse monitoring for safe delivery of outpatient chimeric antigen receptor T-cell (CAR-T) therapy across multiple Sarah Cannon Transplant and Cellular Therapy Network Programs","volume":"30","author":"Cox","year":"2024","journal-title":"Transplant Cell Therapy Off Publ Am Soc For Transplant Cell Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1403249","article-title":"Using technology for patient-centered care at home after CAR T-cell therapy or stem cell transplant: a prospective feasibility study","volume":"16","author":"Moore","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1841031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:57:46Z","timestamp":1783328266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1841031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":54,"alternative-id":["10.3389\/fonc.2026.1841031"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1841031","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"article-number":"1841031"}}